Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 3Unknown 2Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 8Other solid neoplasm 5Tumor-Agnostic 2Lymphoid 2Head & Neck 2Gynecologic 2Dermatologic 2Sarcoma 1NET 1Endocrine 1Breast 1

Conditions

Neoplasm Metastasis 2

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × tislelizumab × Tumor-Agnostic × Clear all
NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Terminated
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

BeOne Medicines

Phase 1 Terminated
99 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡